Clinical trial · Interventional
HopeMove App in Pediatric Cancer Patients
HopeMove: Feasibility and Acceptability of a Mobile Application to Promote Physical Activity in Pediatric Hemotology and Oncology Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot feasibility study aims to assess the acceptability, usability, safety, and initial effects of the HopeMove mobile health app on fatigue in adolescents aged 13 to 18 years undergoing hematology-oncology treatment. HopeMove is a wearable-compatible app that offers guided home exercise sessions and daily symptom tracking to support physical activity and monitor well-being during treatment. The study includes an expert usability evaluation with 10 clinicians, a one-week usability testing phase with 15 adolescents, and an eight-week intervention period in which participants complete at least three exercise sessions per week using the app. Outcomes include usability measured with the Mobile Application Usability Scale, satisfaction assessed via a Visual Analog Scale, and fatigue evaluated with the Fatigue Scale. The findings are expected to provide evidence on the feasibility, usability, and potential clinical benefits of mobile-supported exercise programs for children and adolescents undergoing cancer treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mobile Application | — | UNRESOLVED | — |
| Physical Activity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HopeMove Mobile Application | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention Group-HopeMove Application Group
- description
- Participants assigned to the HopeMove Application Group will use HopeMove, a mobile application designed to promote and support physical activity among pediatric hematology and oncology patients. During the 4-week feasibility period, participants are instructed to engage with the application at least 3 days per week, completing the guided physical activity sessions provided within the app.
- interventionNames
- Other: HopeMove Mobile Application
Primary outcomes (2)
- measure
- Mobile Application Usability
- timeFrame
- Prior to the initiation of the pilot trial (single assessment during the development phase)
- description
- Mobile application usability was evaluated prior to the pilot study by a panel of experts in pediatric oncology, digital health, and user-centered design. Experts assessed the HopeMove application using a standardized usability assessment form that examined clarity of content, ease of navigation, appropriateness for the target age group, visual design, responsiveness, and overall user experience. Feedback from experts was used to refine and optimize the application before initiating the pilot trial.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 13 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adolescents aged 13-18 years * receiving active hematology-oncology treatment * able to use a smartphone running Android operating system * has internet access * voluntarily agrees to participate * parent/guardian consent obtained (if applicable) * able to perform light-moderate exercise * able to complete at least 75% of planned exercise sessions Exclusion Criteria: * having a chronic illness requiring regular invasive procedures, * having received analgesics within the past 2 hours, * having experienced a seizure within the past 2 hours, * using antiepileptic medication, * having a body temperature above 37.5°C * not having parental consent, * being agitated at the time of the procedure, * having any auditory or visual impairments.
References
Publications (0)
Data not yet available